214 related articles for article (PubMed ID: 1988574)
1. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
Kleinerman ES; Snyder JS; Jaffe N
J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
5. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
6. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
8. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
9. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
[TBL] [Abstract][Full Text] [Related]
10. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
Asano T; Kleinerman ES
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Shi F; MacEwen EG; Kurzman ID
Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
[TBL] [Abstract][Full Text] [Related]
12. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
13. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
Mori K; Ando K; Heymann D
Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
Kurzman ID; Shi F; Vail DM; MacEwen EG
Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
[TBL] [Abstract][Full Text] [Related]
15. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
[TBL] [Abstract][Full Text] [Related]
16. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
Anderson P
Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
[TBL] [Abstract][Full Text] [Related]
17. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
19. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
20. [L-MTP-PE--a potential antineoplastic agent].
Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
